Revolution Medicines

Based in California, US, and founded in 2014 by David L. Pompliano, David Pompliano, Mark A. Goldsmith, and Martin D. Burke, Revolution Medicines, Inc. develops medicine for the treatment of cancer, by translating frontier oncology targets. In July 2019, Revolution Medicines, Inc. In February 2020, Revolution Medicines, Inc. The company is listed on Nasdaq under the ticker symbol RVMD and employs approximately x 162 employees. Mark A. Goldsmith is the CEO and president of Revolution Medicines, Inc. Revolution Medicines, Inc. is developing RMC-4630, which is a central node in the RAS signaling pathway, and RMC-4630 for a range of tumor types featuring specific oncogenic mutations. The company is also developing a portfolio of mutant-selective RAS inhibitors that are cell-active inhibitors of the active, GTP-bound form of RAS, or RAS(ON). In addition, the product pipeline of Revolution Medicines includes RMC-5845, a SOS1 selective inhibitor, and RMC-5552, a 4EBP1/mTORC1 selective inhibitor. Revolution Medicines, Inc.983 million in revenue in the fiscal year ended in December 2020.

1. Series C

   Jun 5, 2019

   Amount

   $100M

   Investors

   Locked

2. Series B

   Mar 23, 2018

   Amount

   $56M

   Investors

   Locked

3. Series A

   Dec 20, 2016

   Amount

   $25M

   Investors

   Locked

4. Series A

   Feb 4, 2015

   Amount

   $45M

   Investors

   Locked